The startup has developed a biocompatible gel-particle embolic device that utilizes a catheter system to selectively occlude blood flow in targeted organs, such as the prostate and uterine fibroids. This device effectively controls bleeding and de-vascularizes tumors, minimizing the risk of catheter adhesion and fluid entrapment during procedures.
Funding
$14.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current embolic devices used to occlude blood flow in targeted organs can present challenges such as catheter adhesion and the potential for fluid entrapment, which can complicate procedures and impact patient outcomes. Achieving deep penetration and distal access in the vasculature remains a significant hurdle for effective embolization, particularly in oncology and devascularization applications.
Solution
Fluidx Medical's GPX Embolic Device is designed to provide a deep-penetrating, durable liquid embolic solution for targeted occlusion of blood flow. The device utilizes a biocompatible gel-particle formulation delivered through a catheter system, enabling precise and controlled embolization. This technology aims to minimize the risk of catheter adhesion and fluid entrapment, while maximizing distal reach for effective devascularization of tumors and control of bleeding. The GPX Embolic Device is under development and designed for use in peripheral applications, including oncology.
Target Audience
The primary target audience includes interventional radiologists, vascular surgeons, and interventional oncologists who perform embolization procedures for tumor devascularization, hemorrhage control, and other vascular occlusions.
Features
- Biocompatible gel-particle embolic formulation for targeted and durable occlusion.
- Catheter-based delivery system for precise placement and controlled embolization.
- Designed for deep penetration and distal access within the vasculature.
- Minimizes the risk of catheter adhesion and fluid entrapment during procedures.
- Potential applications include oncology and other devascularization procedures.